Literature DB >> 11684929

Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels.

L Ahdieh Grant1, M J Silverberg, H Palacio, H Minkoff, K Anastos, M A Young, M Nowicki, A Kovacs, M Cohen, A Muñoz.   

Abstract

OBJECTIVE: To characterize predictors and consequences of discontinuing antiretroviral therapy (ART) in terms of CD4 cell count, HIV RNA, and reported side-effects in a large cohort of HIV-infected women.
DESIGN: Cohort study.
METHODS: A total of 1058 HIV-infected women initiated potent ART before September 1999. For each 6 month period after October 1996 we determined the proportion of potent ART users who downshifted to non-potent ART and who discontinued all ART. We examined the role of CD4 cell count and HIV RNA with regard to ART discontinuation.
RESULTS: Between October 1996 and September 1999, 1058 individuals contributed 3362 visits at which potent ART was reported in the previous 6 months. Overall rates of 6 month downshifting and discontinuation were 10.0% and 6.7%. The proportion of individuals discontinuing all ART increased from 2.9% in late 1996 to 9.1% in mid 1999 (P < 0.001). Individuals with high HIV RNA levels were more likely to discontinue (P < 0.05). Compared to those who continued on potent ART, individuals who discontinued experienced large declines (P < 0.001) in CD4 cell counts and were more than three times more likely (P < 0.001) to experience HIV RNA increases. However, over one-third of those discontinuing ART reported side-effects and this subset had smaller CD4 cell count declines as compared to discontinuers not reporting side-effects (P = 0.147).
CONCLUSIONS: In a large cohort of HIV-infected women, an increasing proportion of potent ART users discontinued ART over 3 years. Higher HIV RNA levels predicted discontinuation. Immediate immunological/virological deleterious consequences were observed. Side-effects were the most common reason for discontinuation and CD4 cell count declines were larger among those who did not cite side-effects as the reason for discontinuation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684929     DOI: 10.1097/00002030-200111090-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia.

Authors:  Hasina Samji; Yalin Chen; Kate Salters; Julio S G Montaner; Robert S Hogg
Journal:  AIDS Behav       Date:  2014-11

2.  Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150.

Authors:  Beverly E Sha; Camlin Tierney; Susan E Cohn; Xin Sun; Robert W Coombs; Lisa M Frenkel; Spyros A Kalams; Francesca T Aweeka; Barbara Bastow; Arlene Bardeguez; Anne Kmack; Alice Stek
Journal:  HIV Clin Trials       Date:  2011 Jan-Feb

3.  Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.

Authors:  Alison J Hughes; Christine L Mattson; Susan Scheer; Linda Beer; Jacek Skarbinski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

4.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.

Authors:  Michael J Silverberg; Mary Elizabeth Gore; Audrey L French; Monica Gandhi; Marshall J Glesby; Andrea Kovacs; Tracey E Wilson; Mary A Young; Stephen J Gange
Journal:  Clin Infect Dis       Date:  2004-08-16       Impact factor: 9.079

6.  Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems.

Authors:  T W Kim; A Palepu; D M Cheng; H Libman; R Saitz; J H Samet
Journal:  AIDS Care       Date:  2007-09

7.  Assessing the performance of a computer-based policy model of HIV and AIDS.

Authors:  Chara E Rydzak; Kara L Cotich; Paul E Sax; Heather E Hsu; Bingxia Wang; Elena Losina; Kenneth A Freedberg; Milton C Weinstein; Sue J Goldie
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

Review 8.  Discontinuation from Antiretroviral Therapy: A Continuing Challenge among Adults in HIV Care in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Hailay Abrha Gesesew; Paul Ward; Kifle Woldemichael Hajito; Garumma Tolu Feyissa; Leila Mohammadi; Lillian Mwanri
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

9.  Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts.

Authors:  John D Morris; Elizabeth T Golub; Shruti H Mehta; Lisa P Jacobson; Stephen J Gange
Journal:  AIDS Res Ther       Date:  2007-06-06       Impact factor: 2.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.